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Abstract
Background: The burden of non-communicable diseases is rising globally. This trend seems to be faster in developing countries
of the Middle East. In this study, we presented the latest prevalence rates of a number of important non-communicable diseases
and their risk factors in the Iranian population.
Methods: The results of this study are extracted from the third national Surveillance of Risk Factors of Non-Communicable
Diseases (SuRFNCD-2007), conducted in 2007. A total of 5,287 Iranian citizens, aged 15–64 years, were included in this survey.
Interviewer-administered questionnaires were applied to collect the data of participants including the demographics, diet,
physical activity, smoking, history of hypertension, and history of diabetes. Anthropometric characteristics were measured and
serum biochemistry profiles were determined on venous blood samples. Diabetes (fasting plasma glucose ≥ 126 mg/dl),
hypertension (systolic blood pressure ≥ 140 mmHg, diastolic blood pressure ≥ 90 mmHg, or use of anti-hypertensive drugs),
dyslipidemia (hypertriglyceridemia: triglycerides ≥ 150 mg/dl, hypercholesterolemia: total cholesterol ≥ 200 mg/dl), obesity
(body mass index ≥ 30 kg/m2), and central obesity (waist circumference ≥ 80 cm in females and ≥ 94 cm in males) were identified
and the national prevalence rates were estimated.
Results: The prevalence of diabetes, hypertension, obesity, and central obesity was 8.7% (95%CI = 7.4–10.2%), 26.6% (95%CI
= 24.4–28.9%), 22.3% (95%CI = 20.2–24.5%), and 53.6% (95%CI = 50.4–56.8%), respectively. The prevalence of
hypertriglyceridemia and hypercholesterolemia was 36.4% (95%CI = 34.1–38.9%) and 42.9% (95%CI = 40.4–45.4%), respectively.
All of the mentioned prevalence rates were higher among females (except hypertriglyceridemia) and urban residents.
Conclusion: We documented a strikingly high prevalence of a number of chronic non-communicable diseases and their risk
factors among Iranian adults. Urgent preventive interventions should be implemented to combat the growing public health
problems in Iran.
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Background
Chronic non-communicable diseases (NCDs) such as car-
diovascular disease and diabetes are the leading cause of
death worldwide [1], having comprised 60% of all deaths
in 2005. Approximately 80% of NCD-attributable deaths
are occurring in low and middle-income countries [2].
Furthermore, NCDs were responsible for nearly half of the
burden (measured in disability-adjusted life years
[DALYs]) of diseases in 2005, both worldwide and in low/
middle-income countries [3]. The global prevalence of
NCDs is increasing, with the majority of cases occurring in
developing countries [4]. In this context, the Middle East
is expected to bear one of the world's greatest increases in
the absolute burden of NCDs and their risk factors in the
near future. Most of this increase is anticipated to affect
the economically productive age of 45 to 64 years, in con-
trast to most developed countries in which the increase in
chronic disease burden concerns mainly the ages above 65
years [5-7]. The increasing burden of NCDs is especially
prominent among urban dwellers, and is consistent with
the epidemiological transition from communicable to
non-communicable chronic diseases as the predominant
causes of morbidity in developing populations [8,9]. The
age-standardized death rate attributable to cardiovascular
diseases and diabetes is estimated to be higher than 400
per 100,000 in Iran, one of the largest populations in the
Middle East. The loss of the Iranian gross domestic prod-
uct (GDP) due to heart disease and diabetes in 2015 will
be 167% of that in 2006 [3].
The results of the Asia-Pacific Cohort Studies Collabora-
tion (APCSC) project have improved our insight to the
prevalence of NCDs and their consequences in the Asia-
Pacific region [10]. Overweight and obesity are endemic
problems in much of the region. The population-attribut-
able fractions in this region because of overweight and
obesity is up to 9.2% for coronary heart disease mortality,
2.9% for hemorrhagic stroke mortality, and 10.2% for
ischemic stroke mortality [11]. According to the nation-
ally representative data available from 12 countries in the
region, diabetes has a prevalence of between 2.6% to
15.1%. The population-attributable fractions because of
diabetes is up to 12% for coronary heart disease mortality,
6% for hemorrhagic stroke mortality, and 11% for
ischemic stroke mortality [12]. The prevalence of hyper-
tension in the region is up to 47% in men and 38% in
women. The population-attributable fractions for coro-
nary heart disease mortality, hemorrhagic stroke mortality
and ischemic stroke mortality in men (women) are up to
39%, 66% (49%), and 44% (45%), respectively [13]. The
prevalence of high serum total cholesterol (TC) in the
region ranges from 4% to 27%. Up to 14% and 15%,
respectively, of coronary artery disease mortality and
ischemic disease mortality is attributable to high TC [14].
The results from Middle-Eastern countries are scant,
mainly because of the rarity of nationally representative
data in these countries. In order to determine the magni-
tude of the problem associated with NCDs in the popula-
tion of Iran, the national surveys of NCDs risk factors have
been conducted annually since 2005 under the supervi-
sion and recommendations of the World Health Organi-
zation (WHO). The first, second and the third surveys
were performed in 2005, 2006 and 2007. The third
national Surveillance of Risk Factors of Non-Communica-
ble Diseases (SuRFNCD) provided the demographic,
anthropometric and biochemical characteristics of a
nationally representative sample of 5,278 Iranian adults
aged 15–64 as well as valuable information on their diet
and physical activity. In this study, we aimed to describe
the methodology applied to conduct this survey and to
present the national prevalence of a number of important
non-communicable health problems and their risk factors
including diabetes, hypertension, obesity, central obesity,
and dyslipidemia.
Methods
The third national SuRFNCD was conducted in March
2007 and comprised 5,287 non-institutionalized Iranian
adults aged 15–64 years. Institutionalized individuals
such as soldiers and those living in nursing homes were
not included. After excluding participants aged 15 to 24
years (n = 1,054), analysis was performed on data of the
remaining 4,233 individuals, who were aged 25–64 years.
The reason for this exclusion was related to the relatively
rapidly changing BMI of individuals between 15 and 24
years of age. The appropriate method to define obesity in
this age group is by using percentiles in which case com-
parisons with adult obesity would not be trivial and may
negatively affect the results.
The study was designed based on the STEPwise guidelines
of the WHO [15]. The survey received ethics approval of
the Center for Disease Control (CDC) of Iran and was car-
ried out in collaboration with 40 medical schools across
the country. All participants gave verbal informed con-
sent. The participants were recruited in clusters of 10
males and 10 females living in neighboring households.
The address of the first subject in each cluster was selected
randomly out of the postal addresses and sampling was
continued based on a predetermined schedule to register
all 20 participants. The target population was adults aged
15 to 64 years, classified into 5 ten-year age groups (i.e.
15–24, 25–34, 35–44, 45–54, and 55–64). Each cluster
comprised two males and two females in each age group.
The number of clusters selected from each province was
proportional to the urban/rural size of that province. For
example, 51 clusters were taken from Tehran and only 2
from Ilam (the smallest of the 30 provinces of Iran). TheBMC Public Health 2009, 9:167 http://www.biomedcentral.com/1471-2458/9/167
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participants were visited at their household by interview-
ers who were recommended by the collaborating medical
schools to the managerial team in CDC. Interviewers were
trained and instructed on the details of the survey in a
one-day workshop in Tehran prior to the commencement
of the survey. Informed consents were obtained and the
required information was recorded in the following three
steps. In step 1, general health characteristics and demo-
graphic information were collected by standardized ques-
tionnaires. In step 2, physical examination was performed
to determine weight, height, waist circumference, and
blood pressure. Participants were subsequently invited to
prepare for step 3, i.e. collection of 10–12 hour fasting
blood samples.
Step 1: Demographic Data and Behavioral Assessments
Interviewer-administered questionnaires based on WHO
STEPS instrument (core and expanded) were filled out in
6 different domains: demographic information, diet,
physical activity, tobacco use, history of hypertension,
and history of diabetes. Demographic information was
comprised of insurance coverage and occupation in addi-
tion to sex, age, province of residence, residential area
(urban/rural) and the postal address.
To identify participants with known diabetes mellitus
(KDM), they were asked if a health care professional had
ever told them that they had diabetes. History of diabetes
in the first degree relatives was also recorded. For determi-
nation of access to care, participants were asked whether a
health care professional has told them to have diabetes
during the past 12 month, and whether they have had a
blood glucose test during the past 12 months. Diabetic
individuals were further asked whether their physician
had recommended life style and nutrition modification,
or had prescribed insulin and/or oral agents for them.
Regarding the history of hypertension, consumption of
anti-hypertensive medication in the past 2 weeks, the time
of the most recent blood pressure measurement by a
health care professional, and whether a health care profes-
sional has ever told the participant to have hypertension
were recorded.
Step 2: Physical Examination
Weight and height of participants were determined in
light clothing and without shoes. Portable calibrated elec-
tronic weighing scale and portable measuring inflexible
bars were used. Waist circumference (WC) was measured
using constant tension tape at the end of a normal expira-
tion, with arms relaxed at the sides, at the midpoint
between the lower part of the lowest rib and the highest
point of the hip on the mid-axillary line. Blood pressure
was measured with a calibrated Omron M7 sphygmoma-
nometer (HEM-780-E). The average of three measure-
ments, made at intervals of 5 minutes, was used for
analysis.
Step 3: Biochemical Measurements
10 ml of venous blood was taken in sitting position, col-
lected in 4 tubes, centrifuged immediately, and trans-
ferred under cold chain condition to the Central Reference
Laboratory of Ministry of Health of Iran (Tehran, Iran).
Fasting plasma glucose (FPG), total cholesterol (TC), high
density lipoprotein cholesterol (HDL-C), low density
lipoprotein cholesterol (LDL-C) and triglycerides (TG)
were measured. One tube was treated with 2 μg sodium
fluoride for glucose preservation to enhance the accuracy
of glucose measurement. FPG was measured by the enzy-
matic colorimetric method using glucose oxidize test
(intra- and inter-assay coefficients of variation 2.1% and
2.6%, respectively). Serum TC, TG, LDL-C and HDL-C
were determined by enzymatic methods (Parsazmun,
Karaj, Iran). The two remaining tubes were transferred to
the endocrine laboratory of Vali-Asr hospital (Tehran Uni-
versity of Medical sciences, Tehran, Iran) for insulin, C
reactive protein, and leptin measurements, which are not
the subjects of this report.
Definition of variables
We designated participants as having known diabetes
mellitus (KDM) if a health care professional had ever told
them to have diabetes. In those without KDM, FPG = 126
mg/dl was regarded as newly diagnosed diabetes.
Impaired fasting glucose (IFG) was defined in those with-
out KDM by FPG levels ≥ 100 mg/dl (5.6 mmol/l) but <
126 mg/dl (7.0 mmol/l) [16]. Hypertension was defined
as systolic blood pressure ≥ 140 mmHg, diastolic blood
pressure ≥ 90 mmHg, or current use of anti-hypertensive
drugs. Pre-hypertension was defined as 120 mm Hg ≥
systolic blood pressure < 140 mmHg or 80 mmHg ≤
diastolic blood pressure < 90 mmHg in non-hypertensive
participants [17]. The body mass index (BMI; calculated as
weight/height2) ≥ 30 kg/m2 and 25 ≤ BMI < 30 kg/m2 were
regarded respectively as obesity and overweight [18]. Cen-
tral obesity was defined by the International Diabetes Fed-
eration (IDF) criteria (WC ≥ 80 cm in females and ≥ 94 cm
in males) [19] and the criteria set by the National Choles-
terol Education Program-Third Adult Treatment Panel
(ATP III) criteria (WC ≥ 88 cm in females and ≥ 102 cm in
males) [20]. For high TC, the cut points of 200 mg/dl and
240 mg/dl were considered. High TG was defined as TG ≥
150 mg/dl [19].
Statistical analysis
Complex sample survey analysis was performed in SPSS
16 for Windows (Chicago, IL, USA). To extrapolate the
results to the Iranian adult population, the data were
weighted for age (10-year strata), sex, and residence area
(rural/urban) according to the results of the national cen-BMC Public Health 2009, 9:167 http://www.biomedcentral.com/1471-2458/9/167
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sus of Iran in 2006 (n = 31,409,737, age: 25–64 years
[21]). The complex sample analysis plan was defined
based on the clusters of sampling protocol, strata (age
groups, sex, and residential area) and the determined
weights. National estimates, made in the complex survey
analysis mode, are expressed as mean ± standard error of
the mean (SEM) or prevalence (95%CI).
Results
Since the questionnaires were filled out by interviewers,
missing data were extremely rare. For biochemical meas-
urements, however, 836 (19.7%) participants did not
consent to blood sampling. Biochemical measurements
were thus available for the remaining 3,397 individuals.
As presented in Table 1, the total prevalence of diabetes
was estimated to be 8.7% (95%CI = 7.4–10.2), about half
(47.1%) of which can be attributed to newly diagnosed
disease. The prevalence of diabetes was higher among
older age groups, females, and urban dwellers. The preva-
lence of IFG was 9.2% among non-diabetic individuals.
The national estimate of BMI was 26.47 ± 0.15 kg/m2. The
prevalence of obesity and overweight was 22.3% (95%CI
= 20.2–24.5) and 36.3% (95%CI = 34.6–38.1), respec-
tively. Obesity was more prevalent among females and
urban dwellers (Table 2). The mean WC of Iranian adults
was estimated to be 88.67 ± 0.38 cm. The prevalence of
central obesity, defined by the ATP III and IDF criteria,
were respectively 33.8% (54.4% in females and 13.9% in
males) and 53.6% (73.4% in females and 34.4% in
males) (Table 3). Irrespective of the criteria used, the prev-
alence of central obesity grew with increasing age, and was
higher among females and urban residents.
The estimated systolic and diastolic blood pressure was
122.84 ± 0.57 mmHg and 80.67 ± 0.39 mmHg, respec-
tively. Overall 26.6% (95%CI = 24.4–28.9) of Iranian
adults were estimated to be hypertensive and an addi-
tional 38.2% (95%CI = 36.1–40.2; corresponding to 12
million people) to have prehypertension. Hypertension
was more prevalent among older age groups, females and
urban residents (Table 4).
The national estimates of TG and TC were 148.83 ± 2.45
mg/dl and 195.63 ± 1.10 mg/dl, respectively. The preva-
lence of hypertriglyceridemia, TC ≥ 200 mg/dl, and TC ≥
Table 1: Estimates of prevalence of newly diagnosed diabetes, known diabetes and IFG among Iranian adults 25–64 years old
Impaired Fasting Glucoseab Known DM New DMa New and Known DMa
National 
estimatec
Prevalence
(95% CI)
National 
estimatec
Prevalence
(95% CI)
National 
estimatec
Prevalence
(95% CI)
National 
estimatec
Prevalence
(95% CI)
Age
25–34 
(n = 843)
0.6 5.1 (3.4–7.6) 0.1 0.7 (0.3–1.5) 0.3 2.5 (1.4–4.4) 0.4 3.2 (2.0–5.0)
35–44 
(n = 902)
0.9 10.0 
(7.6–13.0)
0.4 4.9 (3.3–7.3) 0.4 4.3 (3.2–5.8) 0.8 9.2 (7.0–12.1)
45–54 
(n = 869)
0.9 13.6 
(11.5–16.1)
0.5 8.4 (6.7–10.4) 0.4 5.6 (3.5–8.7) 0.9 14.0 
(11.2–17.3)
55–64 
(n = 783)
0.5 14.6 
(11.9–17.9)
0.4 12.1 
(8.2–17.4)
0.2 6.7 (4.9–9.1) 0.6 18.8 
(14.7–23.6)
Sex
Males 
(n = 1645)
1.5 9.3 (7.7–11.3) 0.7 4.4 (3.1–6.1) 0.6 4.0 (3.1–5.2) 1.3 8.4 (6.6–10.5)
Females 
(n = 1752)
1.4 9.0 (7.2–11.3) 0.8 4.9 (3.8–6.2) 0.7 4.2 (2.9–6.0) 1.4 9.1 (7.4–11.2)
Residential 
area
Urban 
(n = 2175)
2.1 9.8 (8.3–11.4) 1.1 4.9 (3.9–6.2) 1.0 4.3 (3.4–5.4) 2.1 9.2 (7.8–10.9)
Rural 
(n = 1222)
0.7 7.8 (5.4–11.1) 0.3 3.9 (2.4–6.1) 0.3 3.7 (2.1–6.3) 0.7 7.5 (5.2–10.9)
Total 
national 
estimate
(n = 3397)
2.9 9.2 (7.9–10.7) 1.5 4.6 (3.8–5.7) 1.3 4.1 (3.3–5.1) 2.7 8.7 (7.4–10.2)
DM: Diabetes mellitus, CI: confidence interval
a In subjects with valid fasting plasma glucose measurements
b In non-diabetic subjects
c Rounded to the nearest million
Estimates are weighted for age, sex, and residential area on the basis of the population of Iran in 2006BMC Public Health 2009, 9:167 http://www.biomedcentral.com/1471-2458/9/167
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240 mg/dl were 36.4% (95%CI = 34.1–38.9), 42.9%
(95%CI = 40.4–45.4), and 14.1% (95%CI = 12.6–15.9),
respectively. Dyslipidemia was more common among
urban dwellers and older age groups. Females had a
higher prevalence of hypercholesterolemia while males
had a higher prevalence of hypertriglyceridemia (Table 5).
Discussion
The WHO STEPS surveillance program was designed to
generate validated and internationally comparable data
about the chronic non-communicable or cardiovascular
diseases particularly for populations with less available
evidences. Our third national SuRFNCD was conducted in
2007 based on the WHO STEPS guidelines. The main
results of this survey indicate the high prevalence of dia-
betes, hypertension, obesity, central obesity, and dyslipi-
demia in Iran. Overall these problems were more
common among females, older age groups, and in urban
areas. In a large study (age: 15–64 years) in the North-East
of Iran, sociodemographic factors such as progressive
urbanization and advancing age were significantly corre-
lated to the increasing prevalence of type 2 diabetes [22].
Table 2: Estimates of prevalence of obesity among Iranian adults 25–64 years old
Obesity Overweighta
National
estimateb
Prevalence
(95% CI)
National
estimateb
Prevalence
(95% CI)
Age
25–34 (n = 1081) 1.8 14.4 (11.5–17.8) 4.1 31.8 (29.0–34.7)
35–44 (n = 1113) 2.4 26.7 (22.7–31.1) 3.5 39.4 (36.1–42.8)
45–54 (n = 1069) 1.8 29.3 (25.6–33.2) 2.5 39.8 (36.4–43.3)
55–64 (n = 970) 0.9 27.4 (24.1–31.0) 1.3 39.3 (35.1–43.6)
Sex
Males (n = 2121) 2.3 14.2 (12.2–16.5) 6.0 37.5 (35.0–40.1)
Females (n = 2112) 4.7 30.6 (27.3–34.0) 5.4 35.1 (32.8–37.6)
Residential area
Urban (n = 2853) 5.3 23.8 (21.5–26.2) 8.6 38.2 (36.2–40.2)
Rural (n = 1380) 1.7 18.5 (14.5–23.4) 2.8 31.7 (28.4–35.3)
Total national estimate
(n = 4233)
7.0 22.3 (20.2–24.5) 11.4 36.3 (34.6–38.1)
CI: confidence interval
a In non-obese subjects
b Rounded to the nearest million
Estimates are weighted for age, sex, and residential area on the basis of the population of Iran in 2006
Table 3: Estimates of prevalence of central obesity defined by the ATP III and the IDF criteria among iranian adults 25–64 years old
High WC by IDFa High WC by ATPIII
National
estimateb
Prevalence
(95% CI)
National
estimateb
Prevalence
(95% CI)
Age
25–34 (n = 1081) 5.0 39.3 (34.2–44.6) 2.7 21.5 (17.5–26.1)
35–44 (n = 1113) 5.3 58.7 (53.7–63.5) 3.3 37.5 (31.8–43.5)
45–54 (n = 1069) 4.2 66.7 (61.2–71.8) 2.9 45.5 (39.0–52.2)
55–64 (n = 970) 2.3 70.0 (64.7–74.7) 1.7 49.5 (42.6–56.5)
Sex
Males (n = 2121) 5.5 34.4 (31.3–37.5) 2.2 13.9 (11.9–16.0)
Females (n = 2112) 1.1 73.4 (69.5–77.0) 8.4 54.4 (50.0–58.8)
Residential area
Urban (n = 2853) 12.6 56.0 (52.5–59.5) 8.0 35.5 (32.0–39.1)
Rural (n = 1380) 4.2 47.5 (40.7–54.4) 2.7 29.8 (23.8–36.5)
Total national estimate
(n = 4233)
16.8 53.6 (50.4–56.8) 10.6 33.8 (30.8–37.1)
WC: waist circumference, CI: confidence interval
a ATP III: Third Adult Treatment Panel; IDF: International Diabetes Federation
b Rounded to the nearest million
Estimates are weighted for age, sex, and residential area on the basis of the population of Iran in 2006BMC Public Health 2009, 9:167 http://www.biomedcentral.com/1471-2458/9/167
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Similarly, the prevalence of diabetes was linked to urban-
ization in a recent study (age > 19 years) in central Iran
[23]. Hypertension was significantly more common
among females than males in another large study (age >
19 years) in central Iran [24]. Speedy urbanization and
advancing age are not the only reasons underlying the
increasing prevalence of NCDs in Iran. Nutritionally-
related health patterns have changed dramatically in the
Middle-East during recent years, partly because of social
development in the absence of steady economic growth.
Changes in dietary and physical activity patterns as well as
inequality in health care are other important factors [25].
In the following sections, our findings are discussed and
compared to the reports from the United States, western
European countries, our Asian neighbors, and other Asian
countries.
Diabetes
The APCSC study reports prevalence rates between 2.6%
and 15.1% for countries in the Asia-Pacific region [12].
We have previously reported the national prevalence of
diabetes as 7.7% (8.3% in females and 7.1% in males, age:
Table 4: Estimates of prevalence of hypertension and pre-hypertension among iranian adults 25–64 years old
Pre-hypertensiona Hypertension
National
estimateb
Prevalence
(95% CI)
National
estimateb
Prevalence 
(95% CI)
Age
25–34 (n = 1081) 5.0 39.0 (35.3–42.8) 1.8 14.0 (11.5–17.0)
35–44 (n = 1113) 3.6 39.8 (36.1–43.7) 2.3 25.2 (22.6–28.1)
45–54 (n = 1069) 2.5 39.1 (35.9–42.4) 2.4 38.4 (35.0–41.9)
55–64 (n = 970) 1.0 28.7 (25.5–32.0) 1.9 56.4 (52.4–60.3)
Sex
Males (n = 2121) 7.1 44.3 (41.3–47.3) 3.9 24.7 (22.1–27.4)
Females (n = 2112) 4.9 31.9 (29.4–34.4) 4.4 28.6 (25.1–32.3)
Residential area
Urban (n = 2853) 8.6 38.0 (35.7–40.4) 6.3 28.2 (25.7–30.9)
Rural (n = 1380) 3.4 38.4 (34.4–42.6) 2.0 22.6 (18.6–27.1)
Total national estimate
(n = 4233)
12.0 38.2 (36.1–40.2) 8.4 26.6 (24.4–28.9)
CI: confidence interval
a In non-hypertension subjects
b Rounded to the nearest million
Estimates are weighted for age, sex, and residential area on the basis of the population of Iran in 2006
Table 5: Estimates of prevalence of high triglycerides levels and hypercholesterolemia among Iranian adults 25–64 years old
Triglycerides ≥ 150 mg/dl Cholesterol ≥ 200 mg/dl Cholesterol ≥ 240 mg/dl
National 
estimatea
Prevalence
(95% CI)
National 
estimatea
Prevalence
(95% CI)
National 
estimatea
Prevalence
(95% CI)
Age
25–34 (n = 843) 3.5 27.1 (23.7–30.7) 3.9 30.2 (26.8–33.7) 1.1 8.8 (6.6–11.6)
35–44 (n = 902) 3.8 42.4 (37.4–47.7) 4.2 46.2 (42.5–50.0) 1.3 14.2 (11.4–17.6)
45–54 (n = 869) 2.7 42.6 (39.3–45.9) 3.4 54.0 (50.3–57.7) 1.2 19.0 (16.6–21.6)
55–64 (n = 783) 1.5 44.5 (40.7–48.4) 2.1 61.6 (56.3–66.6) 0.8 25.4 (21.7–29.5)
Sex
Males (n = 1645) 6.3 39.6 (36.0–43.3) 6.4 40.4 (36.8–44.2) 1.8 11.0 (9.0–13.4)
Females (n = 1752) 5.1 33.2 (30.3–36.2) 7.0 45.4 (42.1–48.7) 2.7 17.3 (15.1–19.8)
Residential area
Urban (n = 2175) 8.8 39.3 (36.4–42.2) 9.9 44.2 (41.4–47.0) 3.2 14.4 (12.7–16.4)
Rural (n = 1222) 2.6 29.3 (26.1–32.8) 3.5 39.6 (34.7–44.6) 1.2 13.4 (10.3–17.3)
Total national estimate
(n = 3397)
11.4 36.4 (34.1–38.9) 13.5 42.9 (40.4–45.4) 4.4 14.1 (12.6–15.9)
CI: confidence interval
a Rounded to the nearest million
Estimates are weighted for age, sex, and residential area on the basis of the population of Iran in 2006 IranBMC Public Health 2009, 9:167 http://www.biomedcentral.com/1471-2458/9/167
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25–64 years) in 2005 [26]. According to the results of the
present study, the prevalence of diabetes is about 8.7% in
Iranians aged 25–64 years old (9.2% in females and 7.5%
in males). A comparison between years 2005 and 2007
can be found in Figure 1. These estimates are a just below
the reported rates from the United States (9.3%; 8.2% in
females and 10.6% in males, age > 20 years) [27], but con-
siderably higher than the estimates made in the UK
(3.4%; age: 30–59 years) [28] and comparable to reports
from Australia (7.4%; 6.8% in females and 8.0% in males,
age range ≥ 25 years) [29]. The prevalence of diabetes in
one of our neighbors, Turkey (11% in both females and
males, age ≥ 35 years) [30], is similar to our prevalence
rates (12.5%; 13.0% in females and 12.1% in males) in
the same age range. Our prevalence rates are higher than
those reported from China (5.5%; 5.8% in females and
5.2% in males, age: 35–74 years) [31] and comparable to
the rates reported from Korea (7.6%; 7.5% in females and
8.1% in males, age ≥ 20 years) [32]. A higher prevalence is
reported in India (12.1%, age ≥ 20 years) [33]. The rising
prevalence of diabetes with increasing age in our study is
consistent with the mentioned reports. The total preva-
lence of diabetes estimated in our study corresponds to
more than 2.7 million adults, about half of whom are
newly diagnosed cases. We further estimated that approx-
imately 2.9 million non-diabetic Iranian adults suffer
from IFG.
Obesity
The APCSC study reports prevalence rates ranging from
less than1% to higher than 20% for countries in the Asia-
Pacific region [11]. Our study demonstrated the preva-
lence of obesity to be 22.3% among Iranian adults (30.6%
in females and 14.2% in males), corresponding to about
7 million individuals. A review in 2005 estimated the
prevalence of obesity among urban Iranians aged 15–70
years to be between 22% and 40% [34]. Another survey
(2004; age: 20–70 years) in the north of Iran reached an
estimate of 27.8% in females and 9.9% in males [35].
According to National Health and Nutrition Examination
Survey (NHANES) of the US, the prevalence of obesity in
individuals aged 20–74 years was 34% in females and
31.7% in males [36]. The corresponding figures in Aus-
tralia (age ≥ 25 years) were 19% and 17%, respectively
[37]. In the UK, the prevalence of obesity was estimated to
be 24.2% in females and 23.7% in males (national Health
Survey, 2006) [38]. Compared to the results from the US
and UK, the prevalence of obesity among Iranian males is
much lower. The higher prevalence of obesity in Iranian
females, compared to males, is in agreement with the
results from most of our neighboring Arab countries,
including Saudi Arabia (24% in females and 16% in
males, age ≥ 15 years) [39], Oman (23.8% in females and
16.7% in males, age ≥ 20 years) [40] and Lebanon (18.8%
in females and 14.3% in males, age ≥ 20 years) [41]. In
Turkey as well, the prevalence of obesity is higher in
females (24.6% vs. 14.4% in males, age ≥ 20 years) [42].
Taken together, the prevalence of obesity among Iranian
females exceeds the rates in females from our neighboring
countries.
Central Obesity
Approximately, 33.8% (54.4% in females and 13.9% in
males, corresponding to more than 10.6 million adults)
of Iranian adult population are centrally obese according
to ATP III definition. A unique finding of our study is the
strikingly higher prevalence of central obesity among
females (about 4 times more than males) compared to
males. A similar ratio (46.2% in females and 10.6% in
males, age: 20–70 years) was obtained in 2004 in a survey
in the north of Iran [35]. The prevalence of ATP III-
defined central obesity was about 38.6% (46.3% in
females and 29.8% in males) in the US [43] and 36.5%
(41% in females and 32% in males) in the UK [38]. In
comparison, central obesity is more common in Iranian
females, and considerably less common in males. The
prevalence of central obesity among females in Turkey
(57.6%), one of our neighbors, is comparable to our esti-
mate. The total prevalence of central obesity (40.9%) and
the prevalence in males (21.2%) in Turkey (age ≥ 20
years) are higher than our estimates for Iran [44]. The
prevalence among Tunisian males (8.8%) is lower than
our estimate (age ≥ 20 years) [45]. Finally, central obesity
Comparison between 2005 and 2007 in prevalence of diabe- tes among Iranian adults Figure 1
Comparison between 2005 and 2007 in prevalence of 
diabetes among Iranian adults. KDM: known diabetes 
mellitus, NDM: newly diagnosed diabetes mellitus, KNDM: 
known and new diabetes mellitus.BMC Public Health 2009, 9:167 http://www.biomedcentral.com/1471-2458/9/167
Page 8 of 10
(page number not for citation purposes)
is significantly less common in the Eastern Asian coun-
tries such as China [46] and Korea [47] than in Iran.
Hypertension
The APCSC study reports prevalence rates between 5%
and 47% in men and between 7% and 38% in women for
countries in the Asia-Pacific region [13]. In our survey the
prevalence rate of hypertension was 26.6% (28.6% in
females and 24.7% in males), corresponding to 8.3 mil-
lion adults. Our previous national estimate (2005) for the
prevalence of hypertension was 25.2% (24.8% in females
and 25.5% in males) [48]. A comparison between years
2005 and 2007 is provided in Figure 2. A systematic
review in 2004 showed that the prevalence of hyperten-
sion varies greatly around the world, lowest in rural India
(6.8% in females and 3.4% in males) and highest in
Poland (72.5% in females and 68.9% in males) [49]. In
Turkey, the prevalence is 31.8% (36.1% in females and
27.5% in males, age ≥ 18 years) [50], which is higher than
our estimate. The prevalence in the 35–64 year old popu-
lation of the US (27.8%; 25.8% in females and 29.8% in
males) was lower than our estimate in a similar age range
(35.3%; 40.1% in females and 30.7% in males), whereas
reports from the UK (41.7%; 36.5% in females and 46.9%
in males), Germany (55.3%; 50.3% in females and 60.2%
in males) and Spain (46.8%; 44.6% in females and 49.0%
in males) point to prevalence rates higher than our esti-
mate [51]. The prevalence of hypertension in China in
2000–2001 (27.2%; 25.8% in females and 28.6% in
males, age: 35–74 years) [52] was similar to our current
estimate. According to the mentioned studies, hyperten-
sion grows in prevalence with increasing age.
Hypertriglyceridemia
Data from previous reports on the prevalence of hypertrig-
lyceridemia in Iran is rare. According to the latest results
of the ongoing Tehran Lipid and Glucose Study (TLGS),
37.6% of Tehranian adolescents (age: 10–19 years) have
TG levels above 110 mg/dl, defined as hypertriglyceri-
demia for their age range [53]. We estimated the preva-
lence of hypertriglyceridemia to be 36.4% among Iranian
adults (33.2% in females and 39.6% in males). The figure
is 30% in the US (age ≥ 20 years) [43], 25% in Sweden
(age: 45–69 years) [54], 19.2% in Italy (age ≥ 20 years)
[55], 12.5% in Switzerland (age: 35–75 years) [56] and
approximately 18% in Portugal (age: 30–70 years) [57].
Our estimate is higher than the mentioned western coun-
tries. Similar reports from Saudi Arabia (40.3%; 33.7% in
females and 47.6% in males) [58], Turkey (30.7%; 26.1%
in females and 36.2% in males) [44] and Lebanon
(35.3%; 22.6% in females and 52.4% in males) [59] sug-
gest that hypertriglyceridemia is a more common problem
in our region than in western countries.
Hypercholesterolemia
Data from previous reports on the prevalence of hyperc-
holesterolemia in Iran is rare. According to the recent
results of TLGS, the mean level of total cholesterol among
Tehranian adult females is approximately 200 mg/dl, sug-
gesting that about half of the female population of Tehran
suffer from hypercholesterolemia [60]. In our survey, the
prevalence of total hypercholesterolemia (TC ≥ 200 mg/
dl) was estimated to be 42.9% (45.4% in females and
40.4% in males). In 2005, The American Heart Associa-
tion (AHA) reported the prevalence of hypercholestero-
lemia to be 48.2% (48.6% in females and 47.8% in
males) in non-Hispanic white Americans aged ≥ 20 [61].
In UK, approximately 48% (48% in females and 48% in
males) of adults aged 19–64 years had hypercholestero-
lemia [62]. The prevalence rates in these two developed
countries, and in a rather similar age range to our study,
are approximately only five percent higher than our esti-
mate in a developing country. The prevalence rate in Por-
tugal (56.7%; age: 30–70 years) [57] and Saudi Arabia
(54%; age: 30–70 years) [58] is also about 10–15% higher
than our prevalence rate. The difference between the latter
two studies and ours of about 5 years in the age range may
explain the difference in prevalence rates. Hypercholeste-
rolemia was present in 32.8% (34.2% in females and
31.6% in males) of the Chinese aged 35–74 years [63],
which is much lower than our estimates and most of the
above countries. The rising trend of hypercholesterolemia
with increasing age was observed in all of the above stud-
ies.
Comparison between 2005 and 2007 in prevalence of hyper- tension among Iranian adults Figure 2
Comparison between 2005 and 2007 in prevalence of 
hypertension among Iranian adults.BMC Public Health 2009, 9:167 http://www.biomedcentral.com/1471-2458/9/167
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Conclusion
We documented a strikingly high prevalence of a number
of chronic non-communicable diseases and their risk fac-
tors in Iran, and showed that the prevalence of these met-
abolic abnormalities in our country, as a developing
country in the nutritional and life style transition phase is
comparable, if not higher, to most developed countries.
With continuation and acceleration of urbanization, the
prevalence of these disease conditions will likely escalate.
Therefore, urgent preventive interventions on a national
scale should target these highly prevalent metabolic
abnormalities (e.g. diabetes, obesity, hypertension, and
dyslipidemia). Based on our results, women and urban
residents need to be the focus of more intensive attention.
The main limitation with our study was the possibility of
recall bias associated with questions regarding past medi-
cal history (e.g. diabetes, hypertension). The other limita-
tion of our results stems from the fact that approximately
one fifth of our participants did not consent to blood sam-
pling. Since only the demographic and anthropometric
characteristics of these individuals were analyzed, addi-
tional sources of bias might have affected our results.
Finally, caution needs to be practiced in inter-country
comparisons which are subject to misinterpretations due
to differences in age groups, study design, sampling
method, and the year in which each survey was carried
out.
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